Margaret joined CTTC in June of 2018 and serves as Alliance Manager for Ancora Innovation, the collaboration with Deerfield Management. Prior to joining CTTC, she was an independent consultant in the oncology sector for biotechnology and pharmaceutical companies. Margaret previously served as vice president of Portfolio and Product Development at Infinity Pharmaceuticals. Prior to Infinity, she was a director at Millennium Pharmaceuticals where she led Cell and Molecular Oncology and was the discovery leader on the VelcadeTM product development team. She started her career in drug discovery at ProScript as a senior scientist and leader of the Cell Cycle team. Before joining the industry, Margaret was an instructor and research fellow at Harvard Medical School.
Margaret brings extensive experience in drug discovery and development to Ancora Innovation, including filing INDs, leading cross-functional project teams through clinical proof-of-concept studies, and bringing a first-in-class drug to market. She holds a bachelor's degree in cell biology from the University of Tennessee and a Ph.D. in pathology from Vanderbilt University.